Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Galantamine Fig1)
Galantamine Tablet, Film Coated
Product Images NDC 72162-2566
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 72162-2566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 10: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 13 Weeks Of Treatment (Galantamine Fig10)
Figure 11: Cumulative Percentage Of Patients Completing 13 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 90%, 24 To 32 mg/day 67%. (Galantamine Fig11)
Figure 12 (Galantamine Fig12)
This text appears to include a range of numbers and symbols followed by some words related to improvement levels such as "Markedly," "Moderately," "Minimally," and "Worse." The text also mentions "CIBIC-plus Rating." It might pertain to a scale or assessment tool measuring changes in a certain condition or response.*
Figure 2: Cumulative Percentage Of Patients Completing 21 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% And 24 mg/day 78%. (Galantamine Fig2)
Figure 3: Distribution Of Cibic-plus Ratings At Week 21 (Galantamine Fig3)
This text provides information about a study or experiment involving different dosages of a substance (possibly a medication) named Placebo. The dosages mentioned are 8 mg/day, 16 mg/day, and 24 mg/day. It also includes a scale for evaluating the effectiveness of the substance on different individuals, ranging from "Markedly Improved" to "Markedly Worse." This assessment scale may be related to the CIBIC-plus Rating system.*
Figure 4: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig4)
Figure 5 (Galantamine Fig5)
This information appears to show the cumulative percentage of patients with different levels of points and changes from baseline in ADAS-cog scores. It includes data points at -10, -7, and -4 points, a category for "No Change," as well as the corresponding percentages of patients for each. Additionally, it indicates the dosage levels of two types of medication: 24mg/day and 32mg/day. The table also includes the ADAS-cog change from baseline, with data points at 10 and 15.*
Figure 6: Distribution Of Cibic-plus Ratings At Week 26 (Galantamine Fig6)
This text shows a chart displaying the percentage of patients at different dosages (40mg and 24mg/day, 32mg/day) in age group 60+ experiencing different changes (Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, Markedly Worse) as per CIBIC-plus Rating.*
Figure 7: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig7)
Figure 8: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 87%, 24 mg/day 80%, And 32 mg/day 75%. (Galantamine Fig8)
This text provides data on the Cumulative Percentage of Patients, with specific details on points, treatment groups (Placebo), and ADAS-cog change from baseline measured at different time points (-5, 0, 5). Overall, it seems to represent a study or analysis on the impact of a certain treatment on patients' cognitive performance.*
Figure 9: Distribution Of Cibic-plus Rating At Week 26 (Galantamine Fig9)
This text appears to be a table showing the percentage of patients across different levels of improvement in a clinical trial. The table includes categories such as placebo dosage, time of administration, and the levels of improvement observed in patients.*
Chemical Structure (Galantamine Str)
Label (Lbl721622566)
Each film-coated tablet contains Galantamine hydrobromide USP equivalent to 8 mg galantamine base. The usual dosage of this medication is provided in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). It is important to keep this medication out of reach of children. The product is manufactured by Bryant Ranch Prepack, Inc. for Aurobindo Pharma Limited in Burbank, CA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
